673 Results for "

K-Ras

" in MedChemExpress (MCE) Product Catalog:
Products (673)

673 Results for "K-Ras" in MCE Product Catalog:

Cat. No.: HY-175870A
CAS No.: 3024878-21-2
Target:  

Ras ERK

Research Areas:  

Cancer

(7R)-Eras-4001 is an orally active KRAS mutant inhibitor with remarkable selectivity for H-RAS and N-RAS. (7R)-Eras-4001 effectively suppresses cancer cell viability by blocking downstream signaling pathways mediated by RAF family proteins, inhibiting the formation of the KRAS G12D-RAF1 RBD complex and the phosphorylation of ERK1/2. (7R)-Eras-4001 induces tumor growth inhibition and regression in a dose-dependent manner, and also reduces plasma ERK1/2 phosphorylation levels. (7R)-Eras-4001 exerts a synergistic effect with anti-PD-1 Cetuximab (HY-P9905). (7R)-Eras-4001 can be used in research on non-small cell lung cancer, pancreatic cancer, colorectal cancer, and ovarian cancer .
loading...
    loading...
Cat. No.: HY-115907
Target:  

Ras ERK Apoptosis

Research Areas:  

Cancer

K20 is a potent and selective KRas G12C inhibitor with an IC50 of 1.16 µM. K20 shows anticancer activity in H358 cells (IC50= 0.78 µM). K20 decreases the levels of phosphorylated Erk and leads to cancer cell apoptosis. K20 suppresses NCI-H358 tumor growth with a TGI of 41% without causing obvious toxicity .
loading...
    loading...
Cat. No.: HY-142160
CAS No.: 2729996-45-4
Purity:  98.94%
Target:  

Raf

Research Areas:  

Cancer

GNE-9815 (compound 7) is a highly selective, pan-RAF inhibitor with good oral bioavailability. GNE-9815 exhibits Ki values of 0.062 and 0.19 nM for CRAF and BRAF, respectively. GNE-9815 combines with MEK inhibitor Cobimetinib (HY-13064) shows synergistic modulation of MAPK pathway. GNE-9815 can be used in studies of KRAS mutant cancers .
loading...
    loading...
Cat. No.: HY-157458
CAS No.: 3054112-59-0
Research Areas:  

Cancer

PDEδ autophagic degrader 1 (compound 12c), an autophagosome-tethering compound (ATTEC). is a potent PDEδ autophagic degrader. PDEδ autophagic degrader 1 reduces the PDEδ protein level through lysosome-mediated autophagy without affecting the PDEδ mRNA expression. PDEδ autophagic degrader 1 suppresses the growth in KRAS mutant pancreatic cancer cells .
loading...
    loading...
Cat. No.: HY-P705319
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: HLA-A*0201; B2M; KRasG12C (KLVVVGACGV)
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-P705350
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: HLA-A*0301; B2M; KRasG12C (VVVGACGVGK)
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-179443
CAS No.: 3092446-09-5
Target:  

SOS1 Ras

Research Areas:  

Cancer

SOS1-IN-25 is an SOS1 inhibitor. SOS1-IN-25 exhibits inhibitory activity against KRAS G12C/SOS1 complex formation (IC50 = 11.11 nM). SOS1-IN-25 leads to a dose-dependent decrease in pERK levels. SOS1-IN-25 can be used for the study of leukemia .
loading...
    loading...
Cat. No.: HY-181555
CAS No.: 3105153-34-9
Target:  

Ras

Research Areas:  

Endocrinology Cancer

IACS-56676 is a selective NRAS G12D inhibitor with a target IC50 of 0.031 μM. IACS-56676 stabilizes the p-loop, maintains key interactions with Asp12, Gly60 and Asp69, and achieves selectivity against wild-type KRAS through substitution targeting Leu95. IACS-56676 can be used in the research of melanoma, hematologic malignancies and thyroid cancer .
loading...
    loading...
Cat. No.: HY-P11901
Target:  

Ras HDAC Apoptosis

Research Areas:  

Cancer

KH-1 is a KRAS G12D/HDAC2 dual-target inhibitor with Kd values of 11.63 nM and 20.17 nM, respectively. KH-1 induces pancreatic cell apoptosis, cell cycle arrest, and inhibits cell proliferation, invasion and migration, as well as suppresses tumor growth in pancreatic cancer xenograft models. KH-1 can be used for the research of pancreatic cancer .
loading...
    loading...
Cat. No.: HY-W142207
CAS No.: 2345-61-1
Target:  

Drug Intermediate

Research Areas:  

Cancer

(E)-3-Chloroacrylic acid is an intermediate. (E)-3-Chloroacrylic acid can be used in the synthesis of Compound 81. (E)-3-Chloroacrylic acid can be used in research on human non-small cell lung cancer with KRAS G12C mutation . (E)-3-Chloroacrylic acid is a substrate of trans-3-chloroacrylic acid dehalogenase (Km = 34 µM) .
loading...
    loading...
Cat. No.: HY-P705030
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: HLA-A*0201; B2M; HPV16-E7 (YMLDLQPET)
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-145320
CAS No.: 2766385-92-4
Purity:  99.08%
TMX-4113 is a FPFT-2216 (HY-145319) (Molecular glue) analog and degrader of PDE6D and CK1α. TMX-4113 does not inhibit the growth of KRAS G12C-dependent cancer cells. TMX-4113 can be used in the research of multiple myeloma, pancreatic ductal adenocarcinoma, non-small cell lung cancer and gastric adenocarcinoma .
loading...
    loading...
Cat. No.: HY-179058
Target:  

Deubiquitinase Ras

Research Areas:  

Cancer

JOSD2-IN-1 (Compound 31) is a covalent JOSD2 inhibitor with an IC50 value of 1.95 μM. JOSD2-IN-1 inhibits JOSD2, thereby down-regulating KRAS expression. JOSD2-IN-1 exhibits significant anti-proliferative activity against HCT116 cells. JOSD2-IN-1 can be used for research on colorectal cancer .
loading...
    loading...
Cat. No.: HY-118692
CAS No.: 299165-92-7
Target:  

Ras SOS1

Research Areas:  

Cancer

DCAI is a KRas inhibitor with a Kd value of 1.1 mM. DCAI directly binds to the Ras protein and competitively inhibits SOS-mediated nucleotide release (IC50 = 155 μM) and exchange reaction (IC50 = 342 μM). DCAI binds to the pocket at the Ras-SOS interface and blocks the formation of the Ras-SOS complex intermediate by impeding salt bridge formation through steric hindrance and the induction of Ras conformational changes. DCAI is used in the study of wild-type and mutant Ras tumors .
loading...
    loading...
Cat. No.: HY-118692A
CAS No.: 1049742-84-8
Target:  

Ras SOS1

Research Areas:  

Cancer

DCAI hydrochloride is a KRas inhibitor with a Kd value of 1.1 mM. DCAI hydrochloride directly binds to the Ras protein and competitively inhibits SOS-mediated nucleotide release (IC50 = 155 μM) and exchange reaction (IC50 = 342 μM). DCAI hydrochloride binds to the pocket at the Ras-SOS interface and blocks the formation of the Ras-SOS complex intermediate by impeding salt bridge formation through steric hindrance and the induction of Ras conformational changes. DCAI hydrochloride is used in the study of wild-type and mutant Ras tumors .
loading...
    loading...
Cat. No.: HY-147008
CAS No.: 2344825-52-9
Purity:  99.66%
XP-524 is a potent BET and EP300 inhibitor. XP-524 shows great tumoricidal activity in vivo. XP-524 prevents KRAS-induced, neoplastic transformation in vivo and extends survival in two transgenic mouse models of aggressive PDAC. XP-524 also enhances the presentation of self-peptide and tumor recruitment of cytotoxic T lymphocytes. XP-524 has the potential for the research of pancreatic ductal adenocarcinoma (PDAC) .
loading...
    loading...
Cat. No.: HY-151517
CAS No.: 2793405-20-4
Purity:  99.60%
Target:  

SOS1 Ras

Research Areas:  

Cancer

SOS1-IN-14 is a potent, selective and orally active SOS1 inhibitor with an IC50 value of 3.9 nM. SOS1-IN-14 can be absorbed in the intestine via a P-glycoprotein-mediated efflux mechanism. SOS1-IN-14 can be used to research KRAS-mutated cancers. SOS1-IN-14 has better potent tumor suppression than BI-3406 (HY-125817) .
loading...
    loading...
Cat. No.: HY-158115
CAS No.: 3002056-30-3
Purity:  98.61%
Target:  

Molecular Glues Raf MEK

Research Areas:  

Cancer

NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors .
loading...
    loading...
Cat. No.: HY-174254
CAS No.: 3099809-16-9
Research Areas:  

Cancer

AKT-IN-28 is an Akt allosteric inhibitor, a derivative of Shikonin (HY-N0822). AKT-IN-28 effectively binds to the allosteric site of Akt through hydrophobic and hydrogen interactions with Kd of 2.07 μM. AKT-IN-28 significantly inhibits Akt activity, induces cell apoptosis, arrests cell cycle in G2/M phase, and suppresses proliferation, migration and metabolism of KRAS mutant colorectal cancer cells .
loading...
    loading...
Cat. No.: HY-175560
CAS No.: 3092445-74-1
Target:  

SOS1 PERK

Research Areas:  

Cancer

SOS1-IN-22 is a son of sevenless homolog 1 (SOS1) inhibitor. SOS1-IN-22 can inhibit KRAS-G12C/SOS1 complex formation with an IC50 value of 40.28 nM. SOS1-IN-22 can reduce phosphorylation ERK levels. SOS1-IN-22 can be used for the research of cancer, such as pancreatic carcinoma and appendiceal carcinoma .
loading...
    loading...